56 results
Direct-acting oral anticoagulants (DOACs) for VTE treatment and prevention - Comparison Table

#DOAC #Anticoagulants #Anticoagulation #VTE #Management
DOACs) for VTE treatment ... and prevention ... - Comparison Table ... VTE #Management #Pharmacology ... #Comparison #Table
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
duration same as for treatment ... Disease Note: Treatment ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... amphotericin B, 3 to 5 mg/kg ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
A summary of the pharmacologic management of acute bleeding and secondary prevention of bleeds in LVAD
summary of the pharmacologic ... of bleeds in LVAD ... Anticoagulation #LVAD ... #Bleeding #Pharmacology ... #Management #Treatment
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
or been newly diagnosed ... following initial diagnosis ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
., 4 mg/kg on days ... Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucoadhesive buccal tablet ... chew, or crush tablet ... mucosal #IDSA #Prevention ... #opportunistic ... infections #HIVAIDS #pharmacology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
Over-anticoagulation can lead ... management #algorithm #pharmacology ... #treatment #medications ... #table #pharmacotherapy
Stress Ulcer Prophylaxis

Stress ulcerations are common in ICU patients and may lead to hemorrhage if not
patients and may lead ... prophylaxis for primary prevention ... ulceration or treatment ... #criticalcare #pharmacology